Portal de Periódicos da CAPES

SARS‐CoV ‐2‐reactive antibody detection after SARS‐CoV ‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

2021; Wiley; Volume: 97; Issue: 1 Linguagem: Inglês

10.1002/ajh.26385

1096-8652

José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, Juan Montoro, Lourdes Vázquez, Ariadna Pérez, Gabriel Martin‐Martin, Ana Facal‐Malvar, Elena Ferrer, María‐Jesús Pascual, Gabriela Sanz‐Linares, Beatriz Gago, Andrés Sánchez‐Salinas, Lucı́a Villalón, Venancio Conesa-García, María Teresa Olave, Javier López‐Jiménez, Sara Marcos‐Corrales, Marta García‐Blázquez, Valentín García‐Gutiérrez, José‐Ángel Hernández‐Rivas, Ana Saus, Ildefonso Espigado, Carmen Alonso, Rafael Hernani, Carlos Solano, Blanca Ferrer Lores, Manuel Guerreiro, Montserrat Ruiz‐García, Juan Luis Muñoz Bellido, David Navarro, Ángel Cedillo, Anna Sureda,

CAR-T cell therapy research

This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia < 1 × 109 /ml (odds ratio [OR] 0.33, 95% confidence interval [95% CI] 0.16-0.69, p = .003), active graft versus host disease (GvHD; OR 0.51, 95% CI 0.27-0.98, p = .04) and vaccination within the first year of transplant (OR 0.3, 95% CI 0.15-0.9, p = .04) associated with lower antibody detection whereas. In ASCT, non-Hodgkin's lymphoma (NHL; OR 0.09, 95% CI 0.02-0.44, p = .003) and active corticosteroid therapy (OR 0.2, 95% CI 0.02-0.87, p = .03) were associated with lower detection rate. We report an encouraging rate of SARS-CoV-2-reactive antibodies detection in these severe immunocompromised patients. Lymphopenia, GvHD, the timing of vaccine, and NHL and corticosteroids therapy should be considered in allo-HSCT and ASCT, respectively, to identify candidates for SARS-CoV-2 antibodies monitoring.